中国医科大学学报2026，Vol.55Issue(5)：385-388,395,5.DOI:10.12007/j.issn.0258-4646.2026.05.001
布鲁顿酪氨酸激酶抑制剂治疗原发中枢神经系统淋巴瘤的研究进展
Research progress of Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma
摘要
Abstract
Primary central nervous system lymphoma(PCNSL)is a highly aggressive extranodal diffuse large B-cell lymphoma.Although sensitive to chemoradiotherapy,traditional standard treatment regimens based on high-dose methotrexate still face challenges,such as high toxicity,high recurrence rate,and poor tolerance in older patients.Given the high frequency of MYD88 and CD79B mutations in PCNSL,Bruton's tyrosine kinase inhibitors(BTKi),with their excellent blood-brain-barrier penetration capabilities,are expected to become an important precision treatment strategy for improving prognosis.In this article,the latest clinical progress of BTKi in the treatment of PCNSL is reviewed.关键词
布鲁顿酪氨酸激酶抑制剂/原发性中枢神经系统淋巴瘤/治疗进展Key words
Bruton's tyrosine kinase inhibitors/primary central nervous system lymphoma/treatment progress分类
医药卫生引用本文复制引用
卞仁杰,孙鹏,王军,颜晓菁..布鲁顿酪氨酸激酶抑制剂治疗原发中枢神经系统淋巴瘤的研究进展[J].中国医科大学学报,2026,55(5):385-388,395,5.基金项目
国家血液系统疾病临床医学研究中心转化研究开放课题面上项目(2020ZKMB06) （2020ZKMB06）
辽宁省科技计划联合计划(2023JH2/101700092) （2023JH2/101700092）
